Plain-English translation of NCT05355701 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Melanoma research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new medication called to see if it can treat advanced cancers that have a specific genetic change called a BRAF alteration. The medication comes as a tablet you take by mouth twice a day, and depending on which part of the study you join, you may also receive other cancer drugs. Researchers want to learn whether this treatment is safe and how well it works against these types of cancer.
Many people with advanced cancers that have BRAF gene changes run out of treatment options when standard therapies stop working. This medication is being studied as a potential new way to help patients whose cancer is no longer responding to available treatments.
You likely qualify if…
You likely don't qualify if…
You would take the medication by mouth twice daily for about 2 years, with some participants also receiving additional cancer drugs by mouth or intravenous infusion. You'll have regular visits to the clinic where the study team monitors how you're responding to treatment and checks for any side effects. The study involves three phases: first, researchers find the right dose; then they test it in combination with other drugs; and finally, they expand to larger groups to confirm the results.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
United States